Latest Direct thrombin inhibitors Stories
-- First BLA submission for an investigational reversal agent for a novel oral anticoagulant RIDGEFIELD, Conn., March 2, 2015 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
British Medical Journal publishes biased article regarding PRADAXA RIDGEFIELD, Conn., July 23, 2014 /PRNewswire/ -- Boehringer Ingelheim (BI) wants to set the record straight following misleading
Additional Novel Oral Anticoagulants are Expected to Gain Approval in China for AF and VTE in the Next Three to Four Years, According to Findings from Decision Resources Group BURLINGTON, Mass.,
Federal Judge Overseeing More than 2,300 Pradaxa Lawsuits Schedules Four Bellwether Trials, First of Which Will Begin in September 2014. Columbus, OH (PRWEB)
As Pradaxa Bleeding Lawsuits Mount, FDA Announces Plan for Large Scale Assessment Comparing Pradaxa Bleeding Rates to Warfarin. Columbus, OH (PRWEB) January
Pradaxa Lawsuits Pending in Federal Litigation Allege the Maker of the Blood Thinner Failed to Provide Adequate Warnings Regarding Pradaxa Bleeding Side Effects, Lack of Antidote to Reverse Hemorrhaging
The Rottenstein Law Group, a Pradaxa law firm, acknowledges that the FDA has conducted extensive research into the topic, but the firm is still actively monitoring reports of side effects and
Parker Waichman LLP is alerting the public about a new review published in the Journal of the American Medical Association (JAMA) that highlights the risks of expedited approval for drugs like
- A woman chauffeur.
- A woman who operates an automobile.